Diligence memo · auto-generated · as of July 2, 2026
Ultivue, Inc.
Ultivue, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Ultivue, Inc. operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ultivue, Inc. has raised $55M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2019-06-13.
Most recent recorded round closed around 2024-07-11.
Valuation (modeled)modeled
Provath models Ultivue, Inc. at approximately $23M (range $6.6M–$42M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.14× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 27 months.
Last raise 24 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 8.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.